Ureter and Renal Pelvis Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Upper tract urothelial carcinoma (UTUC) encompasses malignant tumors arising from the urothelial lining of the renal pelvis and ureter. These tumors account for approximately 5-10% of all urothelial cancers and have an annual incidence of 1-2 per 100,000 in Western countries. UTUC shares histological characteristics with bladder cancer — over 90% are transitional cell (urothelial) carcinomas — but differs importantly in anatomical location, risk stratification, and surgical management. The EAU stratifies UTUC into low-risk (unifocal, small, low-grade, no hydronephrosis) and high-risk (multifocal, large, high-grade, hydronephrosis, prior pelvic radiation) categories, which guide treatment selection. Median age at diagnosis is 70 years; men are affected twice as frequently as women. Contralateral UTUC develops in 2-4% of patients. Bladder cancer develops in 30-40% of patients after treatment for UTUC.

Cigarette smoking is the dominant modifiable risk factor, responsible for approximately 70% of cases through urinary excretion of tobacco carcinogens that chronically expose the urothelium. Aristolochic acid — a nephrotoxin found in traditional herbal preparations (Aristolochia species) and implicated in endemic Balkan nephropathy — is a potent UTUC carcinogen, causing distinctive AA-mutational signatures (A-to-T transversions). Occupational aromatic amine exposure (benzidine, beta-naphthylamine) in rubber, dye, and chemical industries doubles UTUC risk. Lynch syndrome (hereditary MMR deficiency, particularly MSH2 mutations) confers 10-22% lifetime UTUC risk and accounts for approximately 5% of all UTUC cases. Additional risk factors include analgesic nephropathy (phenacetin), cyclophosphamide, and chronic upper tract infections with calculi.

Gross or microscopic hematuria is the presenting symptom in 70-80% of patients and should always prompt upper tract imaging and cystoscopy. Flank or lumbar pain occurs in 20-40% due to ureteral obstruction from the tumor mass or blood clot (clot colic). Obstructive nephropathy from ureteral obstruction may cause hydronephrosis, hydroureter, and deteriorating renal function. A palpable flank mass indicates large or locally advanced disease. Incidental UTUC is increasingly discovered on cross-sectional imaging performed for unrelated indications. Constitutional B symptoms — unexplained weight loss, fatigue, night sweats, and anemia — suggest locally advanced or metastatic disease. Renal pelvis tumors are more often asymptomatic until larger than ureteric tumors, which more commonly present with early obstruction.

CT urography (CTU) with excretory phase imaging is the gold-standard modality for UTUC, achieving >96% sensitivity for detecting renal pelvic tumors and 75% for ureteric lesions. MRI urography is an alternative for patients with contrast allergy or impaired renal function. Urine cytology is highly specific for high-grade UTUC (specificity >99%) but has poor sensitivity (~30%) for low-grade disease. Ureteroscopy with direct visualization and selective upper tract biopsy provides pathological diagnosis and grade assessment. Fluorescence in situ hybridization (FISH) of urine improves sensitivity for low-grade tumors. Molecular testing — FGFR3 mutations, MMR/MSI status — guides systemic therapy selection. AJCC TNM 8th edition staging classifies depth of invasion (Ta-T4) and nodal/distant metastasis. CT chest staging is mandatory for high-risk disease.

Radical nephroureterectomy (RNU) with excision of a bladder cuff is the standard of care for high-risk UTUC, performable laparoscopically or via open approach with equivalent oncological outcomes. Neoadjuvant cisplatin-based chemotherapy (gemcitabine-cisplatin, 4 cycles) is recommended before RNU for cT2-T4 N0 M0 disease, as renal function often precludes cisplatin after nephrectomy. Adjuvant nivolumab (CheckMate 274 trial) reduces recurrence risk after RNU in high-risk pT2/T3/T4 or N+ disease, irrespective of PD-L1 status. For low-risk UTUC, kidney-sparing endoscopic management (ureteroscopic laser ablation) preserves renal function with equivalent recurrence rates. Metastatic UTUC: gemcitabine-cisplatin or carboplatin (cisplatin-ineligible) as first-line; enfortumab vedotin-pembrolizumab combination or erdafitinib (FGFR3-altered) for subsequent lines. Single-dose intravesical mitomycin C immediately post-RNU reduces bladder recurrence by 50%.

The prognosis of urothelial carcinoma of the ureter and renal pelvis (UTUC) is closely correlated with pathological stage at the time of radical nephroureterectomy (RNU). Localized disease (pTa–pT1) has a 5-year overall survival of approximately 70–80%, while pT2 (muscularis invasion) drops to 50–65%. Peripelvic fat or renal parenchymal invasion (pT3) carries a 5-year survival of 30–45%, and locally advanced or node-positive disease below 20%. Distant metastatic UTUC reduces median overall survival to 12–18 months. Approximately 70% of UTUC is high-grade at diagnosis — high-grade tumors are significantly more aggressive and prone to early progression and metastasis compared to the low-grade subset. The POUT randomized trial (2020, Lancet) demonstrated that adjuvant gemcitabine-cisplatin chemotherapy after RNU significantly improved disease-free survival in high-risk patients (pT2–T4, pN+), with hazard ratio of 0.45 — a landmark result establishing adjuvant chemotherapy as standard of care for eligible high-risk UTUC. Neoadjuvant cisplatin-based chemotherapy is preferred when GFR allows, as post-RNU renal function frequently precludes adequate cisplatin dosing. The CheckMate 274 trial established adjuvant nivolumab for high-risk upper tract and urothelial cancer patients regardless of PD-L1 status. FGFR3-mutant metastatic UTUC responds to erdafitinib, with response rates of approximately 40%. Bladder urothelial recurrence occurs in 20–40% of patients within 2 years, necessitating lifelong cystoscopic surveillance. Contralateral upper tract recurrence occurs in approximately 2–6% of patients at 5 years. Lynch syndrome-associated UTUC tends to present at younger age and requires bilateral upper tract surveillance.

Smoking cessation is the single most effective preventive measure, as tobacco carcinogens account for approximately 70% of UTUC cases; risk reduction occurs gradually over 10-15 years after quitting. Avoidance of aristolochic acid-containing herbal remedies is critical, particularly in Asia and Eastern Europe where endemic exposure occurs. Occupational safety measures (protective equipment, substitution of carcinogenic chemicals) reduce aromatic amine exposure in high-risk industries. Individuals with Lynch syndrome should undergo regular upper tract surveillance with annual urine cytology and CTU from age 30-35, or 5 years before the earliest UTUC diagnosis in the family. Adequate hydration (targeting at least 2 liters of urine output daily) dilutes urinary carcinogens and may reduce mucosal contact time. Prompt evaluation of hematuria ensures early detection.

Any episode of painless gross hematuria (visible blood in urine) requires urgent urological evaluation — this symptom should never be attributed to benign causes without excluding UTUC and bladder cancer. Persistent microscopic hematuria detected on dipstick or urinalysis on two or more occasions warrants formal upper tract imaging and cystoscopy. Unexplained unilateral flank or lumbar pain, particularly when constant rather than colicky and without a history of kidney stones, should be investigated. Patients with known Lynch syndrome, prior analgesic abuse, or significant aristolochic acid exposure require regular surveillance even in the absence of symptoms. Recurrent urinary tract infections without an obvious cause, or progressive unexplained renal impairment, also merit urological assessment. Early diagnosis dramatically improves outcomes, as low-stage UTUC is highly curable.